Piper Jaffray Upgrades Corcept Therapeutics (CORT) to Overweight; Sees 167% Upside
Tweet Send to a Friend
Piper Jaffray upgraded Corcept Therapeutics (NASDAQ: CORT) from Neutral to Overweight with a price target of $9.00 (from $2.50), saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
